Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
一项多中心、随机、双盲、安慰剂对照的3期临床试验：在初诊晚期卵巢癌患者中，使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价（FZOCUS-1）：一项多中心、随机、双盲、安慰剂对照试验
期刊:Ca-A Cancer Journal for Clinicians
影响因子:232.4
doi:10.3322/caac.70042
Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning
